Objective: To explore the mechanism of folium sennae, aloe combined with panax quinquefolium in treating functional constipation (FC) based on network pharmacology and molecular docking method. Methods: Retrieval of all chemical components and action targets of folium sennae, aloe combined with panax quinquefolium using Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (tcmsp). Relevant targets for functional constipation were accessed through Gencards, OMIM database, and first-line Western drug targets for the treatment of FC were searched through the drugbank database as a supplement. The STRING data platform was used to construct the interaction network of potential target proteins. Meanwhile, GO (gene ontology) enrichment analysis and KEGG (Kyoto Encyclopedia of Genes and Genomes) signaling pathway data were obtained, and the mechanism of action was analyzed and predicted. The PPI network topology was analyzed by Cytoscape 3.8.0 software, and the network diagram of "component-target-pathway" of FC in the three-drug combination treatment was constructed. Autodock Vina was used for molecular docking to further verify the accuracy of network pharmacological analysis of folium sennae, aloe combined with panax quinquefolium in the treatment of functional constipation. Results: The core active compounds of folium sennae, aloe combined with panax quinquefolium for the treatment of functional constipation are quercetin, kaempferol, β-Carotene and ginsenoside F2, and the core targets include PTGS2, MAPK1, Jun, VEGFA,IL6, etc. KEGG pathway enrichment analysis showed that the key targets of folium sennae, aloe combined with panax quinquefolium in the treatment of FC were mainly enriched in TNF signaling pathway, IL-17 signaling pathway, VEGF signaling pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, etc. Molecular docking results verified that the average value of binding energy for each compound docking to the core target was less than -5kcal/mol with a good binding activity. Conclusion: This study preliminarily revealed the synergistic effect of panax quinquefolium combined with folium sennae and aloe in the treatment of function-
This study aims to assess the risk of colorectal stricture progressing to colorectal neoplasia (CRN) in patients with inflammatory bowel disease (IBD). The literature from PubMed, Embase, Web of Science, and Cochrane Library databases was searched from the date of databases’ creation to 5 November 2022. The Newcastle-Ottawa Scale was used to evaluate the quality of the included literature. Meta-analysis was conducted using the Stata 15 software and R 4.04 software. Two case-control studies and 12 cohort studies were eventually included. Colorectal stricture in patients with IBD increased the risk of progressing to CRN [odds ratio (OR): 1.52, 95% confidence interval (CI): 1.02–2.29, P = 0.042], but was irrelevant to the risk of progressing to ACRN (OR: 3.56, 95% CI 0.56–22.70, P = 0.180). The risk of CRN were further distinguished in patients with ulcerative colitis (UC) and Crohn’s disease (CD) Our findings showed that colorectal stricture may increase the risk of progressing to CRN in patients with UC (OR = 3.53, 95%CI 1.62–7.68, P = 0.001), but was irrelevant to the risk of progressing to CRN in patients with CD (OR = 1.09, 95% CI 0.54–2.21, P = 0.811). In conclusion, colorectal stricture in patients with IBD can be used as a risk factor for predicting CRN but cannot be used as a risk factor for predicting ACRN. Stricture is a risk factor for CRN in patients with UC but not in patients with CD. More prospective, multi-center studies with large samples are expected to confirm our findings.
Crohn's disease is an intestinal inflammatory disease of unknown cause, which is clinically divided into acute phase, subacute phase, and chronic phase. The disease symptoms can invade the entire digestive tract, and the most typical lesions are concentrated at the end of the ileum and its adjacent colon. The main manifestations of patients are diarrhea, abdominal pain, fistulas and perforating inflammation, most of which are in segmental and asymmetrical distribution. The symptoms are characterized by repeated attacks and alternating relief. There is no treatment plan to completely cure Crohn's disease. During pregnancy, the various systems of women's bodies have undergone tremendous changes due to the gestation of the fetus, so various complications are prone to occur, which is an important critical period for women of childbearing age. In addition, there are many contraindications to medication during pregnancy, so the treatment of ulcerative colitis during pregnancy has become a difficult problem. Therefore, urgent research for understanding the incidence, risk and treatment of Crohn's disease during pregnancy based on the existing evidence in practice diagnosis and treatment as well as the pregnancy safety information of relevant therapeutic drugs is required. Such research will help us accurately evaluate the corresponding diagnosis and treatment methods during pregnancy. Moreover, it can provide the best advice and management for patients with Crohn's disease who are pregnant and planning to become pregnant.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.